Format

Send to

Choose Destination
Front Oncol. 2014 Apr 14;4:64. doi: 10.3389/fonc.2014.00064. eCollection 2014.

Targeting PI3K/Akt/mTOR Signaling in Cancer.

Author information

1
Medical Oncology, Fondazione I.R.C.C.S. Policlinico San Matteo University Hospital Foundation , Pavia , Italy.
2
Medical Oncology, Maggiore della Carità Hospital, University of Eastern Piedmont "A. Avogadro" , Novara , Italy.

Abstract

The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and survival, in physiological as well as in pathological conditions (e.g., cancer). Indeed, they are so interconnected that, in a certain sense, they could be regarded as a single, unique pathway. In this paper, after a general overview of the biological significance and the main components of these pathways, we address the present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench.

KEYWORDS:

Akt; PI3K; everolimus; inhibitors; mTOR; novel agents; ridaforolimus; temsirolimus

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center